Assignee
DRAGONFLY THERAPEUTICS INC
US·14 granted patents·52 pending applications·63 citations·filing 2018–2025
Top patents by PatentIndex Score
66 records- 0197US11939384B1Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Mar 26, 2024·9 cites·16 claims
- 0296US11884733B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Jan 30, 2024·10 cites·14 claims
- 0396US11834506B2Multi-specific binding proteins that bind NKG2D, CD16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Dec 5, 2023·16 cites·18 claims
- 0496US11787864B2Heterodimeric Fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Oct 17, 2023·13 cites·13 claims
- 0594US12129300B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Oct 29, 2024·1 cites·8 claims
- 0691US11884732B2Proteins binding HER2, NKG2D and CD16DRAGONFLY THERAPEUTICS INC·Filed 2018·Granted Jan 30, 2024·6 cites·15 claims
- 0787US12384847B2Cancer therapy involving an anti-PD1 antibody and a multi-specific binding protein that binds NKG2D, CD16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·2 cites·20 claims
- 0887US12264200B2Antibody variable domains targeting the NKG2D receptorDRAGONFLY THERAPEUTICS INC·Filed 2023·Granted Apr 1, 2025·0 cites·18 claims
- 0986US2025019444A1Antibody variable domains targeting the nkg2d receptorDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1085US12157771B2Proteins binding NKG2D, CD16 and CLEC12ADRAGONFLY THERAPEUTICS INC·Filed 2021·Granted Dec 3, 2024·1 cites·21 claims
- 1181US12377144B2Methods of treating cancer using multi-specific binding proteins that bind NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2022·Granted Aug 5, 2025·1 cites·20 claims
- 1280US2025154261A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 1379US12275791B2Multi-specific binding proteins that bind HER2, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Apr 15, 2025·1 cites·6 claims
- 1479US12215157B2Multi-specific binding proteins that bind CD33, NKG2D, and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Feb 4, 2025·1 cites·40 claims
- 1576US12384851B2Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 12, 2025·1 cites·30 claims
- 1676US2023391877A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1776US2023357409A1Proteins binding nkg2d, cd16 and nectin4DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1875US2023227562A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 1975US2023303702A1Combination therapy of cancer involving multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2074US12378318B2Proteins binding NKG2D, CD16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Granted Aug 5, 2025·1 cites·11 claims
- 2174US2024228625A1Proteins binding her2, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2274US2024166753A1Multi-specific binding proteins that bind nkg2d, cd16, and a tumor-associated antigen for activation of natural killer cells and therapeutic uses thereof to treat cancerDRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2373US2024270861A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2473US2024360223A1Proteins binding nkg2d, cd16 and baff-rDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 2572US2024018266A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 2671US2022380459A1Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 2766US2021292420A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 2865US2021130474A1Multispecific binding proteins targeting caix, ano1, mesothelin, trop2, or claudin-18.2DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 2964US2024228645A1Antibodies targeting baff-r and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3063US2022089760A1Multi-specific binding proteins that bind bcma, nkg2d and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3163US2025206827A1Multi-specific binding proteins that bind her2, nkg2d, and cd16, and methods of useDRAGONFLY THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 3260US2023250176A1Ppharmaceutical formulations and therapeutic uses of multi-specific binding proteins that bind egfr, nkg2d, and cd16DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3359US2022119533A1Heterodimeric fc-fused proteinsDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 3459US2021261668A1Proteins binding nkg2d, cd16, and egfr, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 3558US2021130496A1Multispecific binding proteins targeting ceaDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3658US2023220106A1Antibodies targeting 5t4 and uses thereofDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 3756US2020277383A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 3856US2023416402A1Methods of treating cancer using multi-specific binding proteins that bind nkg2d, cd16, and her2DRAGONFLY THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3956US2022195065A1Pharmaceutical formulations and dosage regimens for multi-specific binding proteins that bind her2, nkg2d, and cd16 for cancer treatmentDRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4055US2023220084A1Antibodies Targeting CLEC12A and Use ThereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4155US2023203202A1Proteins binding nkg2d, cd16 and 5t4DRAGONFLY THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 4255US2023257467A1Proteins binding nkg2d, cd16 and egfrDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4354US2023279121A1Antibodies targeting egfr and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2021·Application pending·0 cites
- 4453US2020002436A1Proteins binding cd123, nkg2d and cd16DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4552US2020216544A1Proteins binding nkg2d, cd16, and egfr, hla-e, ccr4, or pd-l1DRAGONFLY THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 4652US2024117054A1Proteins binding nkg2d, cd16 and flt3DRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4752US2024228628A9Antibodies targeting flt3 and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 4851US2021206859A1Proteins binding nkg2d, cd16 and a tumor-associated antigenDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 4950US2020376034A1Antibody variable domains targeting cd33, and use thereofDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 5050US2021363261A1Protein binding nkg2d, cd16 and a fibroblast activation proteinDRAGONFLY THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Counts cover granted patents and pending applications in the PatentIndex corpus. How scoring works →